Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.31 |
| ▸ | FURIN | P09958 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL509007 | 0.88 | MAPT (0.36) | MAPTPTGDR2LTA4HFURIN | |
| SCHEMBL509369 | 0.86 | LTA4H (0.33) | MAPTPTGDR2LTA4HMALT1P2RX7 | |
| SCHEMBL10285187 | 0.84 | DRD2 (0.34) | MAPTPTGDR2LTA4HALDH1A1 | |
| SCHEMBL5229156 | 0.83 | P2RX7 (0.36) | MAPTPTGDR2P2RX7KCNH2ALDH1A1 | |
| SCHEMBL5227058 | 0.83 | MAPT (0.34) | MAPTPTGDR2KCNH2 | |
| SCHEMBL509505 | 0.82 | MAPT (0.37) | MAPTPTGDR2KCNH2 | |
| SCHEMBL5227544 | 0.81 | MAPT (0.36) | MAPTPTGDR2KCNH2 | |
| SCHEMBL5231705 | 0.81 | PTGDR2 (0.31) | MAPTPTGDR2LTA4H | |
| SCHEMBL509867 | 0.79 | MAPT (0.40) | MAPTPTGDR2LTA4HKCNH2ALDH1A1 | |
| SCHEMBL509302 | 0.79 | PTGDR2 (0.38) | MAPTPTGDR2KCNH2MAPK8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377556-B1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LTD (GB) | 2007-04-04 | — | — | EP | claimed |
| EP-1762567-A1 | Pyrazole derivatives for treating HIV | Pfizer Limited (GB) | 2007-03-14 | — | — | EP | claimed |
| US-20030100554-A1 | Pyrazole derivatives | JONES LYN HOWARD (GB) | 2003-05-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100554-A1 | Pyrazole derivatives | REV1, SARS1, CYP2F1 | MAPT 2150/4885PTGDR2 3728/4885LTA4H 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.